Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 10/20 | 0.50 |
| ▸ | MTOR | P42345 | 8/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | STK4 | Q13043 | 2/20 | 0.46 |
| ▸ | STK3 | Q13188 | 2/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3878934 | 0.89 | PIK3CA (0.51) | PIK3CAMTORHRH4PIK3CDPIK3CG | |
| SCHEMBL3877689 | 0.87 | MTOR (0.45) | PIK3CAMTORPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL3877647 | 0.87 | HSD11B1 (0.52) | PIK3CAMTORTRPA1PIK3R1 | |
| SCHEMBL3876045 | 0.85 | PIK3CA (0.57) | PIK3CAMTORPIK3CGCNR2STK4 | |
| SCHEMBL3878772 | 0.84 | CNR2 (0.57) | PIK3CAMTORHRH4PIK3CDPIK3CG | |
| SCHEMBL3880570 | 0.82 | KDM4E (0.48) | PIK3CAMTORPIK3CDCNR2STK4 | |
| SCHEMBL5451317 | 0.82 | PIK3CA (0.66) | PIK3CAMTOR | |
| SCHEMBL8012871 | 0.78 | PIK3CA (0.79) | PIK3CAMTORHRH4PIK3CDPIK3CG | |
| SCHEMBL164174 | 0.78 | CYP1A2 (0.56) | PIK3CACNR2TRPA1LRRK2 | |
| SCHEMBL3879649 | 0.77 | TRPV1 (0.50) | PIK3CAMTORCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | claimed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | PIK3CA 1107/4885MTOR 2949/4885HRH4 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.